Karyopharm Therapeutics (NASDAQ:KPTI) Shares Pass Below Two Hundred Day Moving Average – Here’s Why

Karyopharm Therapeutics Inc. (NASDAQ:KPTI)’s share price passed below its 200-day moving average during trading on Thursday . The stock has a 200-day moving average of $9.72 and traded as low as $4.37. Karyopharm Therapeutics shares last traded at $4.95, with a volume of 77,987 shares trading hands.

Analyst Upgrades and Downgrades

A number of research firms recently weighed in on KPTI. Royal Bank of Canada reissued an “outperform” rating and issued a $45.00 target price on shares of Karyopharm Therapeutics in a research note on Thursday, February 20th. HC Wainwright boosted their price target on Karyopharm Therapeutics from $7.00 to $56.00 and gave the company a “buy” rating in a research note on Wednesday, February 26th. Finally, Robert W. Baird dropped their price objective on Karyopharm Therapeutics from $75.00 to $54.00 and set an “outperform” rating for the company in a research note on Monday, March 3rd. One research analyst has rated the stock with a hold rating and four have issued a buy rating to the company. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average price target of $57.50.

Karyopharm Therapeutics Stock Performance

The stock has a 50-day moving average of $6.33 and a 200 day moving average of $9.72. The firm has a market capitalization of $42.42 million, a P/E ratio of -4.85 and a beta of 0.58.

Karyopharm Therapeutics (NASDAQ:KPTI) last released its quarterly earnings results on Wednesday, February 19th. The company reported ($3.60) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($3.90) by $0.30. The business had revenue of $30.54 million during the quarter, compared to the consensus estimate of $30.29 million. On average, equities analysts predict that Karyopharm Therapeutics Inc. will post -0.71 EPS for the current year.

Institutional Trading of Karyopharm Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of KPTI. Velan Capital Investment Management LP acquired a new position in Karyopharm Therapeutics during the 4th quarter worth $27,000. Focus Partners Wealth bought a new stake in shares of Karyopharm Therapeutics during the fourth quarter worth $31,000. TD Waterhouse Canada Inc. acquired a new position in shares of Karyopharm Therapeutics during the fourth quarter valued at $32,000. Two Sigma Advisers LP boosted its holdings in Karyopharm Therapeutics by 145.5% in the fourth quarter. Two Sigma Advisers LP now owns 76,600 shares of the company’s stock valued at $52,000 after acquiring an additional 45,400 shares during the last quarter. Finally, Opti Capital Management LP acquired a new stake in Karyopharm Therapeutics in the fourth quarter worth about $85,000. Institutional investors and hedge funds own 66.44% of the company’s stock.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc, a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1).